MedTrace Logo

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212667 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2012-10-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Conditions

  • Involutional Osteoporosis

Interventions

DRUG

ONO-5920

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Project Leader, Development Planning · Ono Pharmaceutical Co. LtTd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2006-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212667 on ClinicalTrials.gov